The therapeutic potential of targeting AMPK for obesity management is, thus, well-supported by its regulatory influence on enzymes and transcription factors, including acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), PGC-1α, SREBP-1, PPARγ, C/EBPα, and C/EBPβ [3,24,35]. This evidence concerns the gene PRKAA2 and obesity due to melanocortin 4 receptor deficiency.